The Pathologist Workforce in the United States: II. An Interactive Modeling Tool for Analyzing Future Qualitative and Quantitative Staffing Demands for Services

Robboy, Stanley J.; Gupta, Saurabh; Crawford, James M.; Cohen, Michael B.; Karcher, Donald S.; Leonard, Debra G.B.; Magnani, B; Novis, David A.; Prystowsky, Michael B.; Powell, Suzanne Zein-Eldin; Gross, David J.; Black-Schaffer, W. Stephen

doi:10.5858/arpa.2014-0559-oa

Cited by 54 publications

(52 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the USA, it is predicted that pathologist workforce demand will have increased by 16% by 2030,5 while numbers of pathologists per capita decline. In their November 2016 publication, ‘Testing times ahead?…”

Section: Strategic Contextmentioning

confidence: 99%

Future-proofing pathology: the case for clinical adoption of digital pathology

2017

View full text Add to dashboard Cite

This document clarifies the strategic context of digital pathology adoption, defines the different use cases a healthcare provider may wish to consider as part of a digital adoption and summarises existing reasons for digital adoption and its potential benefits. The reader is provided with references to the relevant literature, and illustrative case studies. The authors hope this report will be of interest to healthcare providers, pathology managers, departmental heads, pathologists and biomedical scientists that are considering digital pathology, deployments or preparing business cases for digital pathology adoption in clinical settings. The information contained in this document can be shared and used in any documentation the reader wishes to present for their own institutional case for adoption report or business case.

show abstract

Section: Strategic Contextmentioning

confidence: 99%

Future-proofing pathology: the case for clinical adoption of digital pathology

2017

View full text Add to dashboard Cite

show abstract

“…24 Our model adjusts for differences in utilization and the projected change in the insurance mix (provided by the Centers for Medicare and Medicaid Services).…”

Section: Methodsmentioning

confidence: 99%

“…We have reported supply 11 and demand 24 for the specialty of pathology using this model. This report describes the interactive model itself and its methodological origins.…”

Section: Introductionmentioning

confidence: 99%

An Innovative Interactive Modeling Tool to Analyze Scenario-Based Physician Workforce Supply and Demand

Gupta¹,

Black-Schaffer

Crawford

et al. 2015

Academic Pathology

Self Cite

View full text Add to dashboard Cite

Effective physician workforce management requires that the various organizations comprising the House of Medicine be able to assess their current and future workforce supply. This information has direct relevance to funding of graduate medical education. We describe a dynamic modeling tool that examines how individual factors and practice variables can be used to measure and forecast the supply and demand for existing and new physician services. The system we describe, while built to analyze the pathologist workforce, is sufficiently broad and robust for use in any medical specialty. Our design provides a computer-based software model populated with data from surveys and best estimates by specialty experts about current and new activities in the scope of practice. The model describes the steps needed and data required for analysis of supply and demand. Our modeling tool allows educators and policy makers, in addition to physician specialty organizations, to assess how various factors may affect demand (and supply) of current and emerging services. Examples of factors evaluated include types of professional services (3 categories with 16 subcategories), service locations, elements related to the Patient Protection and Affordable Care Act, new technologies, aging population, and changing roles in capitated, value-based, and team-based systems of care. The model also helps identify where physicians in a given specialty will likely need to assume new roles, develop new expertise, and become more efficient in practice to accommodate new value-based payment models.

show abstract

“…Rezultati patohistoloških pretraga odlučuju o daljnjem zbrinjavanju pacijenta, a iskorišteni na pravi način mogu uštedjeti i do 30 % troškova zbog nepotrebnih ili netočnih pretraga, katkada potencijalno štetnih za pacijenta 1 . Zbog toga je svaki napis, pa tako i ovaj koji služi unapređenju razumijevanja i upotrebe patohistološkog nalaza, u ovom slučaju, karcinoma prostate, dobrodošao u svakodnevnoj kliničkoj praksi svih zdravstvenih djelatnika koji skrbe o pacijentu.…”

Section: Uvodunclassified

Pathohistological diagnosis of prostate cancer

2017

View full text Add to dashboard Cite

Sažetak. Rak prostate najčešći je malignom u muškaraca u Europi i SAD-u, raznolik u kliničkoj prezentaciji, patohistološkoj slici, obrascima rasta i širenja. Kada se rak prostate otkrije u ranom stadiju postotak izlječenja je visok. Definitivna verifikacija je patohistološka s individualnom procjenom agresivnog potencijala tumora kroz prognostičke parametre kao što su Gleasonov gradus/gradusna skupina, postotak i broj zahvaćenih cilindara tumorom u iglenoj biopsiji, stadij i pozitivan rub kod prostatektomije. Ovi čimbenici danas značajno utječu na izbor i protokole terapija, ali u ranom stadiju ne mogu prepoznati lokalizirani, klinički značajan karcinom koji će sigurno izazvati metastatku bolest te zahtijeva liječenje. Stoga su se istraživanja danas usredotočila na molekularne biomarkere koji su važni u prognozi, patogenezi te kao ciljne molekule za moguću terapiju. Članak pridonosi boljem razumijevanju patohistološkog nalaza i novih činjenica u molekularnoj patogenezi tumora, što je važno za zbrinjavanje pacijenata s rakom prostate.Ključne riječi: karcinom prostate; molekularni biomarkeri; prognostički čimbenici Abstract. Prostate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis relies on prostate specific antigen serum test, digito-rectal and ultrasound exmination. Definitive verification is pathohistological with individual assesment of aggressiveness of the tumor potential through prognostic parameters such as Gleason gradus/grade groups, percentage and number of affected cilinders in the biopsy, stage and positive margins in prostatectomy. These parameters significantly affect the choice and protocol of therapies but can not identify a localized, clinically significant cancer that will certainly cause metastatic disease and require treatment. Therefore, researchers focused on molecular biomarkers that are important in prognosis, pathogenesis, and as a target molecules for possible therapy. The article contributes to a better understanding of the pathohistological findings and new facts about the molecular pathogenesis of tumors, which are important for the care of patients with prostate cancer.

show abstract

The Pathologist Workforce in the United States: II. An Interactive Modeling Tool for Analyzing Future Qualitative and Quantitative Staffing Demands for Services

Cited by 54 publications

References 33 publications

Future-proofing pathology: the case for clinical adoption of digital pathology

Future-proofing pathology: the case for clinical adoption of digital pathology

An Innovative Interactive Modeling Tool to Analyze Scenario-Based Physician Workforce Supply and Demand

Pathohistological diagnosis of prostate cancer

Contact Info

Product

Resources

About